Physician profile
Eben Feinstein
NPI 1578553905
$805.06
in general payments reported to CMS, 2019-2025
12 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.16 · 2022: $90.24 · 2023: $193 · 2024: $274 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.05 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $214.13 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Fresenius USA Marketing, INC. | $137.69 | 2022-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $120.90 | 2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $81.34 | 2023-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $31.36 | 2025 | |
| Glaxosmithkline, LLC. | $26.40 | 2022 | |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Novo Nordisk INC | $24.01 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $18.47 | 2025 | Farxiga |
| Amgen INC. | $16.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eben Feinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.